Science

AI Can Help COVID-19 Clinical Decision Making, Feinstein Institutes Research Shows

Friday, July 10, 2020 - 5:05pm

Those decisions, along with relevant clinical data and outcomes, could be harnessed to develop novel clinical ML tools.

Key Points: 
  • Those decisions, along with relevant clinical data and outcomes, could be harnessed to develop novel clinical ML tools.
  • With abundant electronic medical data, evidence-based prediction tools can facilitate medical decision making during challenging times, said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes.
  • The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.
  • Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine.

Company Profile for Reven, LLC

Friday, July 10, 2020 - 3:40pm

Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado, based operating company Reven, LLC, is a biopharmaceutical company.

Key Points: 
  • Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado, based operating company Reven, LLC, is a biopharmaceutical company.
  • Revens vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases.
  • Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world.
  • Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering PAD and other cardiovascular related medical conditions.

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Friday, July 10, 2020 - 2:00pm

The options were granted as an inducement equity award outside of the Companys 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and were made as an inducement material to the acceptance of employment with the Company by the new employee.

Key Points: 
  • The options were granted as an inducement equity award outside of the Companys 2013 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4), and were made as an inducement material to the acceptance of employment with the Company by the new employee.
  • The options are subject to the terms and conditions of a stock option agreement covering the grant and the GlycoMimetics, Inc. Inducement Plan, which was adopted January 22, 2020 and provides for the granting of stock options to new employees.
  • The stock option award has an exercise price equal to the closing price of the Companys common stock on July 06, 2020.
  • GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist.

Quantum Sensors Market Analysis Highlights the Impact of COVID-19 2020-2024 | Rising Investments in Quantum Technology to Boost Market Growth | Technavio

Friday, July 10, 2020 - 2:45pm

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • View the full release here: https://www.businesswire.com/news/home/20200710005110/en/
    Technavio has announced its latest market research report titled Global Quantum Sensors Market 2020-2024 (Graphic: Business Wire)
    Although the COVID-19 pandemic continues to transform the growth of various industries, the immediate impact of the outbreak is varied.
  • Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis.
  • Rising investments in quantum technology have been instrumental in driving the growth of the market.

Modernizing Medicine to Host Must-Attend Event on COVID-19 Vaccine Timeline and Contact Tracing with Special Guest Jerome Kim, MD

Friday, July 10, 2020 - 1:02pm

The session, World War C: Contact Tracing and the Hunt for a Vaccine, will take place virtually on Tuesday, July 14 at 7 PM EDT.

Key Points: 
  • The session, World War C: Contact Tracing and the Hunt for a Vaccine, will take place virtually on Tuesday, July 14 at 7 PM EDT.
  • View the full release here: https://www.businesswire.com/news/home/20200710005076/en/
    Jerome Kim, MD, will be the special guest during Modernizing Medicines webinar, World War C: Contact Tracing and the Hunt for a Vaccine, on July 14 at 7 PM EDT.
  • (Photo: Business Wire)
    Modernizing Medicines Chief Medical and Strategy Officer and co-founder, Michael Sherling, MD, MBA, will speak with special guest, Jerome Kim, MD, director general of the International Vaccine Institute (IVI), about the latest pandemic news.
  • He led the Armys Phase III HIV vaccine trial (RV144) which was the first demonstration that an HIV vaccine could protect against infection.

V Foundation Wine Celebration Answer for Cancer Symposium Goes Virtual for 2020

Friday, July 10, 2020 - 1:01pm

The V Foundation Wine Celebration is going virtual on August 8, 2020 by presenting MOMENTUM 2.0, an immersive, digital auction experience supporting the V Foundations fight to achieve Victory Over Cancer.

Key Points: 
  • The V Foundation Wine Celebration is going virtual on August 8, 2020 by presenting MOMENTUM 2.0, an immersive, digital auction experience supporting the V Foundations fight to achieve Victory Over Cancer.
  • Each year, as part of the annual event, the V Foundation Wine Celebration hosts the Answer for Cancer research symposium, where world-class researchers present cutting-edge information to the general public.
  • Please subscribe to the V Foundation Wine Celebrations YouTube channel www.youtube.com/user/winecelebration to view the program.
  • The V Foundation Wine Celebration has raised more than $115 million for cancer research over the last 21 years.

Worldwide Molecular Sieves Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com

Friday, July 10, 2020 - 12:15pm

The "Molecular Sieves - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Sieves - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Molecular Sieves estimated at US$3.6 Trillion in the year 2020, is projected to reach a revised size of US$5.1 Trillion by 2027, growing at a CAGR of 5% over the analysis period 2020-2027.
  • This segment currently accounts for a 18% share of the global Molecular Sieves market.
  • China, the world second largest economy, is forecast to reach an estimated market size of US$1.1 Trillion in the year 2027 trailing a CAGR of 7.9% through 2027.

Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program

Friday, July 10, 2020 - 12:30pm

Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) today provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral mucositis in cancer patients.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (Oragenics or the Company) today provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral mucositis in cancer patients.
  • The Company expects to continue to comply with any applicable regulatory requirements with respect to discontinuing the clinical trial.
  • In addition, Oragenics has an exclusive worldwide channel collaboration with ILH Holdings, Inc. relating to the development of novel antibiotics.
  • Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein, except as required by law.

Inscopix Announces Collaboration With Bruker for Advanced Analysis of Brain Circuits by Combining Miniature Microscopes With Multiphoton Microscopy

Friday, July 10, 2020 - 10:00am

Inscopix today announced a collaboration with Bruker Corporation (NASDAQ: BRKR) for its new Multimodal Image Registration and Analysis (MIRA) platform.

Key Points: 
  • Inscopix today announced a collaboration with Bruker Corporation (NASDAQ: BRKR) for its new Multimodal Image Registration and Analysis (MIRA) platform.
  • We are very excited to announce the launch of the MIRA platform and the collaboration with Bruker, a leader in multiphoton imaging-based applications for neuroscience, said Kunal Ghosh, Ph.D., CEO and founder of Inscopix.
  • Inscopix empowers the development of next-generation therapeutics for difficult-to-treat brain disorders by enabling innovative research and predictive preclinical therapeutic development.
  • Driven by a North Star of overcoming historic challenges in the field, Inscopix provides validated solutions for real-time mapping of neural activity in brain circuits.

Bioasis and Chiesi Group to Host Webcast on July 16, 2020

Thursday, July 9, 2020 - 10:24pm

Under the terms of the Research Collaboration and License Agreement (the Agreement), Chiesi Group will pay Bioasis an upfront payment of US$3 million.

Key Points: 
  • Under the terms of the Research Collaboration and License Agreement (the Agreement), Chiesi Group will pay Bioasis an upfront payment of US$3 million.
  • Chiesi Group will be responsible for all costs associated with research, development and commercialization of the four undisclosed LSD programs.
  • A replay of the webcast (using the same link provided) will be available for one month following the conclusion of the event.
  • Chiesi Global Rare Diseases is a business unit of the Chiesi Group, established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders.